Equities

Joint Corp

JYNT:NAQ

Joint Corp

Actions
Health CareHealth Care Providers
  • Price (USD)11.73
  • Today's Change0.16 / 1.38%
  • Shares traded18.09k
  • 1 Year change+26.81%
  • Beta1.5812
Data delayed at least 15 minutes, as of Nov 22 2024 20:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Joint Corp had net income fall from a gain of 626.71k to a loss of 9.75m despite a 16.24% increase in revenues from 101.25m to 117.70m. An increase in the selling, general and administrative costs as a percentage of sales from 83.15% to 83.27% was a component in the falling net income despite rising revenues.
Gross margin90.70%
Net profit margin-13.95%
Operating margin-4.75%
Return on assets-18.92%
Return on equity-60.51%
Return on investment-30.06%
More ▼

Cash flow in USDView more

In 2023, Joint Corp increased its cash reserves by 82.12%, or 8.66m. The company earned 14.68m from its operations for a Cash Flow Margin of 12.47%. In addition the company generated 174.12k cash from financing while 6.19m was spent on investing.
Cash flow per share-0.7374
Price/Cash flow per share--
Book value per share1.37
Tangible book value per share1.08
More ▼

Balance sheet in USDView more

Joint Corp uses little debt in its capital structure as supported by a debt to capital ratio of 0.22%.
Current ratio1.44
Quick ratio--
Total debt/total equity0.0022
Total debt/total capital0.0022
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -1,675.21%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-915.44
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.